BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32297626)

  • 1. A caged E3 ligase ligand for PROTAC-mediated protein degradation with light.
    Kounde CS; Shchepinova MM; Saunders CN; Muelbaier M; Rackham MD; Harling JD; Tate EW
    Chem Commun (Camb); 2020 May; 56(41):5532-5535. PubMed ID: 32297626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.
    Lin Z; Garcia BA; Lv D
    Angew Chem Int Ed Engl; 2024 Jan; 63(3):e202316581. PubMed ID: 38059785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation.
    Ottis P; Toure M; Cromm PM; Ko E; Gustafson JL; Crews CM
    ACS Chem Biol; 2017 Oct; 12(10):2570-2578. PubMed ID: 28767222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HaloTag-Targeted Sirtuin-Rearranging Ligand (SirReal) for the Development of Proteolysis-Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)*.
    Schiedel M; Lehotzky A; Szunyogh S; Oláh J; Hammelmann S; Wössner N; Robaa D; Einsle O; Sippl W; Ovádi J; Jung M
    Chembiochem; 2020 Dec; 21(23):3371-3376. PubMed ID: 32672888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
    Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
    Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
    Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
    Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation.
    Kannt A; Đikić I
    Cell Chem Biol; 2021 Jul; 28(7):1014-1031. PubMed ID: 33945791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.
    Hu Z; Crews CM
    Chembiochem; 2022 Jan; 23(2):e202100270. PubMed ID: 34494353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E3 ligase ligand chemistries: from building blocks to protein degraders.
    Sosič I; Bricelj A; Steinebach C
    Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An In Vitro Pull-down Assay of the E3 Ligase:PROTAC:Substrate Ternary Complex to Identify Effective PROTACs.
    Bondeson DP; Smith BE; Buhimschi AD
    Methods Mol Biol; 2021; 2365():135-150. PubMed ID: 34432242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High throughput E3 ligase degron binding assays for novel PROTAC ligand discovery.
    Guenette RG; Potts PR
    Methods Enzymol; 2023; 681():23-39. PubMed ID: 36764759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules.
    Hickey CM; Digianantonio KM; Zimmermann K; Harbin A; Quinn C; Patel A; Gareiss P; Chapman A; Tiberi B; Dobrodziej J; Corradi J; Cacace AM; Langley DR; Békés M
    Nat Struct Mol Biol; 2024 Feb; 31(2):311-322. PubMed ID: 38177675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of a fluorescent probe to develop a fluorescence polarization assay for the E3 ligase FEM1C.
    Seipp EK; Huang R
    Bioorg Med Chem; 2023 Jul; 90():117371. PubMed ID: 37339537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.
    Ward CC; Kleinman JI; Brittain SM; Lee PS; Chung CYS; Kim K; Petri Y; Thomas JR; Tallarico JA; McKenna JM; Schirle M; Nomura DK
    ACS Chem Biol; 2019 Nov; 14(11):2430-2440. PubMed ID: 31059647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating Ligands for Ubiquitin Ligases Using Affinity Beads.
    Dobrodziej J; Dong H; Zimmermann K; Hickey CM
    Methods Mol Biol; 2021; 2365():59-75. PubMed ID: 34432239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.
    He Q; Zhou L; Yu D; Zhu R; Chen Y; Song M; Liu X; Liao Y; Ding T; Fan W; Yu W
    J Med Chem; 2023 Aug; 66(15):10458-10472. PubMed ID: 37279091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances of Degradation Technologies Based on PROTAC Mechanism.
    Xiao M; Zhao J; Wang Q; Liu J; Ma L
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystallization of VHL-based PROTAC-induced ternary complexes.
    Wijaya AJ; Farnaby W; Ciulli A
    Methods Enzymol; 2023; 681():241-263. PubMed ID: 36764760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.